文献速递产科母胎医学

分娩时合并癌症患者母婴发病率与死亡率

Maternal morbidity and mortality among patients with cancer at time of delivery.
PubMed 文献 · Am J Obstet Gynecol · 2023-06-07

本研究利用美国全国住院患者样本(2007–2018年)分析分娩住院期间合并癌症的诊断率及母婴结局。在9,418,761例分娩住院中,每10万例分娩有63例合并癌症诊断;癌症患者发生严重母婴发病率(调整OR 5.25)和死亡(调整OR 67.5)的风险显著升高。白血病患者的不良母婴结局风险最高(调整率每1000例分娩113例)。

要点

  • 分娩住院中合并癌症诊断率为每10万例分娩63例(95%CI 60–66)。
  • 癌症患者严重母婴发病率调整OR为5.25(95%CI 4.73–5.83)。
  • 癌症患者死亡调整OR为67.5(95%CI 45.1–101.4)。

核心结论

  • 分娩住院期间合并癌症的患者发生严重母婴发病率和全因死亡的风险显著升高,且风险在不同癌症类型间分布不均。

研究设计与样本

  • 利用美国全国住院患者样本(National Inpatient Sample),识别2007年至2018年间分娩相关住院,采用临床分类软件(Clinical Classifications Software)定义合并癌症诊断,使用调查加权多变量逻辑回归模型计算调整率及调整比值比(OR)。
  • 样本共纳入9,418,761例分娩相关住院。

主要发现

  • 每10万例分娩中63例合并癌症诊断(95%CI 60–66;全国加权估计46,654,042)。
  • 最常见的癌症类型为乳腺癌(每10万例分娩8.4例)、白血病(8.4)、霍奇金淋巴瘤(7.4)、非霍奇金淋巴瘤(5.4)和甲状腺癌(4.0)。
  • 癌症患者发生任何严重母婴发病率的调整OR为5.25(95%CI 4.73–5.83),死亡的调整OR为67.5(95%CI 45.1–101.4)。
  • 癌症患者中,子宫切除术(调整OR 16.92;95%CI 13.96–20.52)、急性呼吸窘迫(调整OR 12.76;95%CI 9.92–16.42)、脓毒症(调整OR 11.91;95%CI 8.68–16.32)和栓塞(调整OR 11.12;95%CI 6.94–17.82)的风险尤其升高。
  • 按癌症类型评估时,白血病患者的不良母婴结局风险最高(调整率每1000例分娩113例;95%CI 91–135)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Individuals with cancer during pregnancy are a medically complex patient population that is anticipated to grow. A better understanding of this population and patterns of risk at time of delivery would offer an opportunity for providers to mitigate maternal morbidity. OBJECTIVE: This study aimed to estimate the prevalence in the United States of concurrent cancer diagnoses at time of delivery by cancer type and associated maternal morbidity and mortality. STUDY DESIGN: Using the National Inpatient Sample, we identified delivery-associated hospitalizations between 2007 and 2018. Concurrent cancer diagnoses were classified using the Clinical Classifications Software. Main outcomes included severe maternal morbidity, as defined by the Centers for Disease Control and Prevention indicators, and mortality during delivery hospitalization. We calculated adjusted rates for cancer diagnosis at time of delivery and adjusted odds ratios of severe maternal morbidity and maternal death during hospitalization using survey-weighted multivariable logistic regression models. RESULTS: In this sample of 9,418,761 delivery-associated hospitalizations, 63 per 100,000 deliveries had a concurrent cancer diagnosis (95% confidence interval, 60-66; national weighted estimate, 46,654,042). The most common cancer types were breast cancer (8.4 per 100,000 deliveries), leukemia (8.4 per 100,000 deliveries), Hodgkin lymphoma (7.4 per 100,000 deliveries), non-Hodgkin lymphoma (5.4 per 100,000 deliveries), and thyroid cancer (4.0 per 100,000 deliveries). Patients with cancer were at significantly higher risk for any severe maternal morbidity (adjusted odds ratio, 5.25; 95% confidence interval, 4.73-5.83) and maternal death (adjusted odds ratio, 67.5; 95% confidence interval, 45.1-101.4). Risks of hysterectomy (adjusted odds ratio, 16.92; 95% confidence interval, 13.96-20.52), acute respiratory distress (adjusted odds ratio, 12.76; 95% confidence interval, 9.92-16.42), sepsis (adjusted odds ratio, 11.91; 95% confidence interval, 8.68-16.32), and embolism (adjusted odds ratio, 11.12; 95% confidence interval, 6.94-17.82) were particularly heightened among patients with cancer. Patients with leukemia, specifically, had the highest risk of adverse maternal outcomes (adjusted rate, 113 per 1000 deliveries; 95% confidence interval, 91-135 per 1000) when evaluating risk by cancer type. CONCLUSION: Patients with cancer are at markedly increased risk of maternal morbidity and all-cause mortality during delivery-associated hospitalization. Risk is distributed unevenly within this population, with certain cancer types carrying unique risks for specific morbidity events.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Sundermann AC, Cate JM, Campbell AK, et al. Maternal morbidity and mortality among patients with cancer at time of delivery. Am J Obstet Gynecol. 2023. PMID: 37295633. doi:10.1016/j.ajog.2023.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。